Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Orgenesis Inc.

ORGSNASDAQ
Healthcare
Biotechnology
$0.57
$0.42(283.33%)
U.S. Market is Open • 10:06

Orgenesis Inc. Fundamental Analysis

Orgenesis Inc. (ORGS) shows weak financial fundamentals with a PE ratio of -0.30, profit margin of -104.45%, and ROE of -16.83%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio0.01

Areas of Concern

ROE-16.83%
Operating Margin-101.20%
Current Ratio0.25
We analyze ORGS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -11857.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-11857.7/100

We analyze ORGS's fundamental strength across five key dimensions:

Efficiency Score

Weak

ORGS struggles to generate sufficient returns from assets.

ROA > 10%
-3.80%

Valuation Score

Excellent

ORGS trades at attractive valuation levels.

PE < 25
-0.30
PEG Ratio < 2
0.01

Growth Score

Weak

ORGS faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

ORGS shows balanced financial health with some risks.

Debt/Equity < 1
-1.08
Current Ratio > 1
0.25

Profitability Score

Weak

ORGS struggles to sustain strong margins.

ROE > 15%
-1683.22%
Net Margin ≥ 15%
-104.45%
Positive Free Cash Flow
No

Key Financial Metrics

Is ORGS Expensive or Cheap?

P/E Ratio

ORGS trades at -0.30 times earnings. This suggests potential undervaluation.

-0.30

PEG Ratio

When adjusting for growth, ORGS's PEG of 0.01 indicates potential undervaluation.

0.01

Price to Book

The market values Orgenesis Inc. at -0.79 times its book value. This may indicate undervaluation.

-0.79

EV/EBITDA

Enterprise value stands at 0.31 times EBITDA. This is generally considered low.

0.31

How Well Does ORGS Make Money?

Net Profit Margin

For every $100 in sales, Orgenesis Inc. keeps $-104.45 as profit after all expenses.

-104.45%

Operating Margin

Core operations generate -101.20 in profit for every $100 in revenue, before interest and taxes.

-101.20%

ROE

Management delivers $-16.83 in profit for every $100 of shareholder equity.

-16.83%

ROA

Orgenesis Inc. generates $-3.80 in profit for every $100 in assets, demonstrating efficient asset deployment.

-3.80%

Following the Money - Real Cash Generation

Operating Cash Flow

Orgenesis Inc. generates limited operating cash flow of $-2.65M, signaling weaker underlying cash strength.

$-2.65M

Free Cash Flow

Orgenesis Inc. generates weak or negative free cash flow of $-3.02M, restricting financial flexibility.

$-3.02M

FCF Per Share

Each share generates $-0.58 in free cash annually.

$-0.58

FCF Yield

ORGS converts -5.69% of its market value into free cash.

-5.69%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.30

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.79

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.61

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.08

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.25

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-16.83

vs 25 benchmark

ROA

Return on assets percentage

-3.80

vs 25 benchmark

ROCE

Return on capital employed

28.91

vs 25 benchmark

How ORGS Stacks Against Its Sector Peers

MetricORGS ValueSector AveragePerformance
P/E Ratio-0.3029.43 Better (Cheaper)
ROE-1683.22%800.00% Weak
Net Margin-10445.47%-20145.00% (disorted) Weak
Debt/Equity-1.080.30 Strong (Low Leverage)
Current Ratio0.254.64 Weak Liquidity
ROA-380.44%-17936.00% (disorted) Weak

ORGS outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Orgenesis Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ